Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a report issued on Saturday.
SHPG has been the topic of a number of other reports. HSBC lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, September 27th. Zacks Investment Research raised shares of Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a research report on Tuesday, July 5th. Jefferies Group reissued a “buy” rating and issued a $262.00 price objective on shares of Shire PLC in a research report on Tuesday, September 20th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire PLC in a research report on Monday, October 3rd. Five research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 194.50 on Friday. The stock has a 50 day moving average price of $195.56 and a 200-day moving average price of $187.04. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The company has a market capitalization of $57.93 billion, a PE ratio of 40.42 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. During the same period in the prior year, the company posted $2.63 EPS. The firm’s revenue for the quarter was up 55.9% on a year-over-year basis. Analysts forecast that Shire PLC will post $12.92 EPS for the current year.
The company also recently announced a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a $0.139 dividend. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is 15.63%.
Several large investors have recently bought and sold shares of the company. Canal Insurance CO bought a new stake in Shire PLC during the second quarter valued at approximately $102,000. FTB Advisors Inc. increased its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. bought a new stake in Shire PLC during the second quarter valued at approximately $111,000. Quadrant Capital Group LLC increased its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC bought a new stake in Shire PLC during the second quarter valued at approximately $114,000. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.